[Role of NO in essential hypertension].
Hirata
Yasunobu
Y
Department of Cardiovascular Medicine, University of Tokyo.
D000319:Adrenergic beta-Antagonists / Q000494:pharmacology / Q000627:therapeutic use; D000818:Animals; D002121:Calcium Channel Blockers / Q000494:pharmacology / Q000627:therapeutic use; D004730:Endothelium, Vascular / Q000502:physiology / Q000503:physiopathology; D006801:Humans; D006973:Hypertension / Q000188:drug therapy / Q000209:etiology* / Q000503:physiopathology; D018919:Neovascularization, Physiologic; D009569:Nitric Oxide / Q000378:metabolism / Q000502:physiology*; D012307:Risk Factors; D014664:Vasodilation
D000319:Adrenergic beta-Antagonists; D002121:Calcium Channel Blockers; D009569:Nitric Oxide